optimal dosing

Related by string. * OPTIMAL . Optimal : optimal dosing regimen . Optimal IdM . Kronos Optimal Health . Optimal Hospice . neurofeedback biofeedback Optimal Functioning . Optimal Geomatics . OpSource Optimal On / dosed . Dosing . Doser . DOSS . doss . Doss : Ann Doss Helms . convenient dosing regimen . dosing interval . dosing instructions . dosing intervals . By ERIN DOSS * optimal dosing regimens *

Related by context. All words. (Click for frequent words.) 70 pharmacodynamic markers 69 efficacy tolerability 67 tolerated dose MTD 67 pharmacodynamic effects 66 dosage regimens 66 endothelin antagonists 66 maximally tolerated dose 65 pharmacokinetic parameters 65 Poly ICLC 65 Maximum Tolerated Dose MTD 65 pharmacodynamics PD 64 Panzem R NCD 64 vidofludimus 64 enzastaurin 64 Bezielle 64 pharmacodynamic PD 64 eniluracil 64 antitumor effect 64 CR# vcMMAE 63 alvespimycin 63 nab paclitaxel 63 pharmacodynamic profile 63 incyclinide 63 eTag assays 63 dosing regimens 63 optimal dosing regimen 63 ritonavir boosted danoprevir 63 oral deforolimus 63 intermittent dosing 63 tanespimycin 63 ELACYT 63 analgesic efficacy 63 TOLAMBA 63 intranasal delivery 63 GAMMAGARD 63 Azedra 63 antiviral efficacy 62 pharmacokinetics PK 62 optimal dosing regimens 62 TACI Ig 62 forodesine 62 lapatinib Tykerb 62 pharmacodynamic properties 62 Ceplene/IL-2 62 Octreolin 62 systemically administered 62 pharmacodynamic parameters 62 clevidipine 62 riociguat 62 visilizumab 62 preclinically 62 adecatumumab 62 MAGE A3 ASCI 62 RG# ITMN 62 neratinib 62 GAP #B# 62 otelixizumab 62 ZOLINZA 62 investigational therapies 62 safety tolerability pharmacokinetic 62 clinical pharmacology studies 62 HCV protease inhibitors 62 CBLC# 62 viral kinetics 61 oral ridaforolimus 61 STRIDE PD 61 MORAb 61 pharmacokinetics pharmacodynamics 61 dose escalation 61 systemic immunosuppressive drugs 61 sunitinib malate 61 CIMZIA ™ 61 hypofractionated 61 noninferiority 61 CTAP# Capsules 61 ADME properties 61 ganetespib 61 selective modulator 61 HGS# 61 biodistribution 61 nonclinical studies 61 oral methylnaltrexone 61 novel VDA molecule 61 Androxal ® 61 sorafenib tablets 61 eprotirome 61 registrational 61 teriflunomide 61 PXD# 61 Phase IIIb clinical 61 torezolid phosphate 61 rt PA 61 Tasigna prolongs 61 RIGScan CR 61 aplindore 61 HGS ETR2 61 subcutaneous SC 61 PRT# 61 Neuradiab 61 ONCONASE R 61 intensive lipid lowering 61 Phase IIB 61 INCB# [001] 61 liposomal formulation 61 thorough QT 61 tezampanel NGX# 61 CINTREDEKIN BESUDOTOX 61 dose proportionality 61 antitumor efficacy 61 predictive biomarkers 61 efficacy 60 CoFactor 60 YONDELIS 60 oral prodrug 60 tolerability pharmacokinetics 60 HAART regimens 60 REOLYSIN ® 60 bortezomib Velcade 60 immunomodulatory therapy 60 placebo controlled clinical 60 INVEGA ® 60 GnRH antagonist 60 mTOR inhibition 60 Pharmacokinetic studies 60 AZILECT R 60 MMP inhibitors 60 antiangiogenic agents 60 indibulin 60 epigenetic therapies 60 Phase Ib II 60 pharmacokinetic PK 60 velafermin 60 inhaled iloprost 60 edifoligide 60 epoetin alpha 60 genotypic resistance 60 dosage regimen 60 cilengitide 60 CCX# 60 pharmacokinetic interactions 60 REMINYL ® 60 tecarfarin 60 adjuvant therapies 60 Allovectin 7 ® 60 oral rivaroxaban 60 confirmatory clinical 60 phase IIb clinical 60 Phase IIb clinical trials 60 non nucleoside 60 pertuzumab 60 MGd 60 phase Ib 60 safety tolerability pharmacokinetics 60 NP2 Enkephalin 60 CG# [003] 60 histone deacetylase inhibitor 60 coadministration 60 ataluren 60 tipranavir 60 limiting toxicity 60 phase IIa clinical 60 cystinosis patients 60 dosing schedules 60 Tyrima 60 galiximab 60 SUTENT ® 60 HuLuc# 60 Onconase 60 GLPG# 60 sipuleucel T 59 lomitapide 59 tumor histology 59 Ceflatonin 59 ALTTO 59 APTIVUS 59 pharmacodynamic endpoints 59 Androxal TM 59 Ophena TM 59 pain palliation 59 Telintra 59 intravenous methylnaltrexone 59 rFIXFc 59 molecular biomarkers 59 dose regimens 59 CYT# QbG# 59 Vidaza azacitidine 59 eliglustat tartrate 59 PREOS 59 cediranib 59 antithrombotic therapy 59 Intravenous CP 59 maximal tolerated 59 Tasimelteon 59 endoscopic gastric ulcers 59 CIMZIA TM 59 OMAPRO 59 subcutaneous PRO 59 imexon 59 Traficet EN 59 dose titration 59 intravesical 59 pharmacokinetic profiles 59 ruxolitinib 59 pharmacokinetic PK profile 59 tremelimumab 59 prognostic indicators 59 lenalidomide dexamethasone 59 immune modulating 59 PROCHYMAL 59 MyVax R 59 rBChE 59 cardioprotective effects 59 rNAPc2 59 HER2 expression 59 anti coagulant therapy 59 KRAS status 59 tasimelteon 59 bicifadine 59 C1 INH 59 Zevalin consolidation 59 Vaxfectin TM 59 warfarin anticoagulation 59 BLA filing 59 Phase #b/#a 59 favorable pharmacokinetic profile 59 GRAVITAS trial 59 NGX# 59 antidepressant efficacy 59 orally administered inhibitor 59 ancrod 59 Asentar 59 Trofex 59 EmbraceAC 59 Hedgehog inhibitor 59 thromboprophylaxis 59 pharmacokinetic profile 59 Archexin 59 Proellex TM 59 Omacetaxine mepesuccinate 59 canakinumab 59 phase IIIb 59 Plicera 59 Corlux 59 neoadjuvant 59 oral picoplatin 59 Q#IR 59 ISTODAX 59 REG1 59 interferon gamma 1b 59 pharmacokinetic pharmacodynamic 59 ixabepilone 59 dose cohort 59 ospemifene 59 imetelstat 59 APRISO 59 generation purine nucleoside 59 anti leukemic 59 pharmacokinetic characteristics 59 motesanib 59 CorVue ™ 59 tolerability 59 vitro dissolution 59 androgen suppression 59 adjuvant radiation 59 multidose 59 ENRICH trial 59 AAG geldanamycin analog 59 stratifying patients 59 LUX Lung 59 ulimorelin 59 vorinostat 59 temsirolimus 59 MIRCERA 59 Phase Ib study 59 CINQUIL 59 cannabinor 59 Cimzia TM 58 subcutaneous formulation 58 elotuzumab 58 Chemophase 58 IMA# 58 Phase IIb III 58 randomized controlled clinical trials 58 plasma pharmacokinetics 58 HuMax EGFr 58 fallopian tube cancers 58 HGS ETR1 58 cardiac repolarization 58 LE DT 58 tezampanel 58 #D#C# 58 Phase 2a clinical trials 58 plasma kallikrein inhibitor 58 PSMA ADC 58 ganaxolone 58 PEARL SC 58 Ophena 58 Afatinib 58 virological response 58 atacicept 58 mesalazine 58 eptifibatide 58 nalbuphine ER 58 EFAPROXYN 58 dexpramipexole 58 insulin sensitizing 58 bolus dose 58 randomized blinded 58 blinded randomized 58 phase IIb trial 58 GLYX 58 gemcitabine Gemzar ® 58 lucinactant 58 budesonide foam 58 personalized immunotherapy 58 K ras mutations 58 PIX# [002] 58 PEG SN# 58 antiangiogenic therapy 58 MyVax ® 58 dosing cohort 58 IIa trial 58 ADAGIO study 58 posaconazole 58 selenium supplementation 58 rindopepimut 58 Cytolin R 58 genotoxicity 58 squalamine 58 velafermin belinostat 58 Multimeric 58 r hGH 58 Orazol 58 radiolabeled TM# 58 Menerba 58 Phase 1b trial 58 BRAF inhibitors 58 NATRECOR ® 58 CYT# potent vascular disrupting 58 AEG# 58 enzyme inhibition 58 Seliciclib 58 factorial design 58 aerosolized KL4 surfactant 58 limiting toxicity DLT 58 lesinurad 58 Allovectin 7 R 58 physiologically relevant 58 p# biomarker 58 Vidofludimus 58 busulfan 58 antiresorptive 58 ACCORD Lipid 58 chemosensitivity 58 vivo potency 58 samalizumab 58 reduce serum phosphate 58 NEUVENGE 58 confirmatory Phase III 58 convenient dosing regimens 58 AZILECT ® 58 genomic biomarker 58 decitabine 58 Perforomist ™ Inhalation Solution 58 BrachySil TM 58 prophylactic antibiotic 58 liposomal doxorubicin 58 SNT MC# 58 sorafenib Nexavar 58 colorectal liver metastases 58 Randomized trials 58 endothelin antagonist 58 axitinib 58 intravenous dosing 58 clinical endpoints 58 Icatibant 58 ORMD 58 NOX E# 58 fulvestrant 58 ticagrelor Brilinta 58 blinded randomized placebo controlled 58 TNF alpha inhibitor 58 QT QTc 58 rHuPH# 58 olaparib 58 estramustine 58 thymalfasin 58 pharmacokinetic equivalence 58 subcutaneous infusion 58 ARIKACE ™ 58 humanised monoclonal antibody 58 RLY# 58 SCH # 58 TPI ASM8 58 Pemetrexed 58 antitumor activity 58 nonrandomized 58 Phase III randomized controlled 58 Tarceva TM 58 antiangiogenic 58 docetaxel Taxotere ® 58 CCR5 inhibitor 58 identifier NCT# 58 prucalopride 58 isoflavone supplement 58 urocortin 2 58 mealtime insulin 58 Aggrastat ® tirofiban hydrochloride 58 teduglutide 58 psychotherapeutic interventions 58 superficial bladder cancer 58 cysteamine bitartrate 58 aflibercept 58 metabolic parameters 58 preclinical pharmacokinetic 58 GTC recombinant human 58 ritonavir boosting 58 lintuzumab 58 Triapine R 58 VAPRISOL 58 BEXXAR Therapeutic Regimen 58 neurologic progression 58 hENT1 58 Combination therapy 58 TLK# 58 Surfaxin LS 58 ReN# 58 GnRH agonists 58 Aurexis 58 hyperphenylalaninemia HPA due 58 GFT# 58 EGFR TKIs 58 Forodesine HCl 58 mTOR kinase 58 SYMMETRY trial 57 Capesaris 57 Cloretazine ® 57 preclinical efficacy 57 Phase 2a trial 57 GMX# 57 pomalidomide 57 Linjeta TM 57 OvaRex R 57 JAK2 inhibitor 57 anti angiogenic agents 57 opioid analgesia 57 chemopreventive agent 57 GRNVAC1 57 HCD# [002] 57 cMET 57 tumor subtypes 57 BRIM2 57 anti angiogenic drugs 57 pharmacodynamics 57 dose limiting toxicities 57 male hormonal contraceptive 57 MAXY G# 57 Phase #/#a clinical 57 antifungal therapy 57 trial evaluating PRX# 57 IDO inhibitor 57 budesonide MMX Phase III 57 dosing frequency 57 prognostic markers 57 oral FTY# 57 JAK inhibitor 57 HIF PH inhibitors 57 CA4P 57 LEP ETU 57 Genasense ® 57 DCCR 57 cortical stimulation 57 PRECISE Trial 57 peptide antigens 57 Insulin PH# 57 active comparator 57 ALA PDT 57 unblinding 57 Diamyd ® 57 gemcitabine chemotherapy 57 Ranolazine 57 protease inhibitor PI 57 human microdosing 57 Anturol TM 57 gefitinib Iressa 57 XmAb# 57 MEK inhibitor RDEA# 57 adipiplon 57 secondary efficacy endpoint 57 custirsen 57 nicardipine 57 fidaxomicin Phase 3 57 prognostic biomarker 57 chemoprevention trials 57 arzoxifene 57 Prosaptide 57 HCV protease 57 Genasense ® oblimersen 57 abacavir lamivudine 57 erlotinib Tarceva ® 57 phase IIb study 57 paclitaxel Taxol ® 57 Diamyd r vaccine 57 PET tracers 57 vandetanib 57 SERMs 57 CA9 SCAN 57 iniparib 57 IMGN# 57 PRTX 57 SERCA2a 57 postoperative chemotherapy 57 APPRAISE 57 neuroprotective properties 57 figitumumab 57 systemic toxicity 57 immunological responses 57 EGFR mutation status 57 corticosteroid therapy 57 nonpharmacologic 57 PRIMO CABG2 57 tolerability profiles 57 deforolimus 57 CRMD# 57 Pralatrexate 57 MGN# 57 severe gastroparesis 57 multicenter Phase II 57 CEQ# 57 p# inhibitor 57 Foradil Aerolizer 57 renal toxicity 57 vicriviroc 57 peg interferon 57 Glybera 57 mechanistic insights 57 direct thrombin inhibitors 57 efficacy endpoint 57 adjuvant therapy 57 rALLy trial 57 nucleoside analog 57 leukotriene receptor antagonist 57 pharmacokinetic studies 57 thoracoscopic lobectomy 57 Amigal 57 FRAGMIN 57 FOLOTYN ® 57 pitavastatin 57 MEK inhibitors 57 randomizing patients 57 iii GTx 57 Intravail R 57 placebo controlled studies 57 Phase #/#a trial 57 Xanafide 57 Zerenex 57 omega interferon 57 varespladib 57 receptor inhibitor 57 EGFR TKI 57 immunosuppressive regimens 57 Phenoptin 57 combinability 57 viral kinetic 57 dosing regimen 57 topical NSAIDs 57 beclomethasone dipropionate 57 TLR agonists 57 relapsed MM 57 radiolabeled 57 uric acid lowering 57 BARI 2D 57 tolerability profile 57 antibody MAb 57 Advagraf 57 DermaVir Patch 57 factor Xa inhibitor 57 depsipeptide 57 evaluating tivozanib 57 Ataluren 57 TOCOSOL Camptothecin 57 EVIZON 57 SILENOR 57 TBC# 57 Lovaxin C 57 BCG refractory 57 ATL# [002] 57 inhibitor RG# 57 randomized multicenter trial 57 chemopreventive agents 57 atrasentan 57 Enzastaurin 57 TAXUS VI 57 Cloretazine R 57 lorvotuzumab mertansine 57 CYP#D# genotype 57 investigational humanized monoclonal antibody 57 Secondary efficacy endpoints 57 pregabalin Lyrica 57 KAPIDEX 57 Preclinical studies suggest 57 treating enlarged prostates 57 ispinesib administered 57 HCV SPRINT 57 angiogenesis inhibitor 57 THR beta agonist 57 EndoTAGTM 1 57 IV bolus 57 AKT inhibitor 57 TORISEL 57 TransVax ™ 57 imatinib therapy 57 bevacizumab Avastin Genentech 57 Tumor Response 57 zileuton 57 recurrent metastatic 57 corticosteroid dexamethasone 57 EchoCRT 57 concurrent chemoradiation 57 OMP #M# 57 obatoclax 57 verteporfin 57 Kamada AAT 57 ZACTIMA 57 IRX 2 57 Amplimexon 57 LHRH antagonists 57 cytoreduction 57 denileukin diftitox 57 antidiabetic drugs 57 adenoma recurrence 57 phase IIa 57 DSMB recommended 57 PEGPH# 57 leflunomide 57 either acutely decompensated 57 topical calcineurin inhibitors 57 Panzem R 57 randomized Phase 2b 57 DPX Survivac 57 CIMZIA TM certolizumab pegol 57 prospectively defined 57 vernakalant hydrochloride 57 insulin detemir 57 hypoxic tumors 57 pimozide 57 zileuton injection 57 immunotherapeutic vaccine 57 warfarin therapy 57 thetreatment 57 PSN# [002] 57 urinary N telopeptide 57 oral PrEP 57 ALV# 57 biologic therapy 57 fibrate drugs 57 prophylactic therapy 57 trials RCTs 57 GRNCM1 57 pharmacogenetic testing 56 APOPTONE 56 surrogate markers 56 injectable formulations 56 standard chemotherapy regimens 56 mycophenolate mofetil MMF 56 oral salmon calcitonin 56 AZOR 56 RISPERDAL ® 56 Pafuramidine 56 Vasogen Celacade 56 ADVEXIN therapy 56 antiepileptics 56 BRAF inhibitor 56 alkylating agent 56 oral antiviral 56 ritonavir boosted 56 recurrent malignant glioma 56 OnDose TM 56 receptor tyrosine kinase inhibitor 56 synthetic retinoid 56 Eniluracil 56 DAPT 56 Phase Ib clinical trials 56 blinded placebo controlled 56 VKORC1 56 reslizumab 56 MYLOTARG 56 pegfilgrastim 56 BRIM3 56 VADT 56 antiarrhythmic drug 56 DU #b 56 QuadraSphere 56 AIM HIGH 56 eribulin mesylate 56 NeuroSTAT ® 56 pharmacodynamic 56 orBec 56 Cotara 56 mTOR inhibitors 56 TroVax ® 56 Panzem NCD 56 TLR antagonists 56 ongoing Phase 1b 56 IMC A# 56 alfa 2a 56 Protelos 56 aldosterone antagonists 56 DNA methylation markers 56 HCV RESPOND 2 56 cintredekin besudotox 56 microdose 56 overlapping toxicities 56 ASSERT trial 56 trastuzumab Herceptin ® 56 docetaxel Taxotere 56 talactoferrin 56 XYOTAX TM 56 Vectibix monotherapy 56 myopathy rhabdomyolysis 56 TELINTRA 56 Degarelix 56 BENICAR HCT 56 Bicifadine 56 thrombolytic agents 56 severe hypersensitivity reactions 56 MAA submission 56 Virulizin ® 56 atherosclerosis regression 56 sitaxsentan 56 fosbretabulin 56 paclitaxel poliglumex 56 MADIT II 56 nebulization 56 eritoran 56 Metastatic colorectal cancer 56 NTx ® -# 56 oral mTOR inhibitor 56 mg/m2 cohort 56 Solorel TM 56 BEXXAR therapeutic regimen 56 metreleptin 56 therapeutic regimens 56 PREZISTA r 56 BAY #-# 56 midstage trials 56 ENMD # 56 Phase 2b study 56 RSD# oral 56 homocysteine lowering 56 TransVax tm 56 Phase 1b dose escalation 56 sd rxRNA 56 BoNTA 56 BCIRG 56 Arikace 56 CCR5 mAb 56 CIMZIA R 56 postmarketing surveillance 56 oral dnaJP1 56 PRADAXA 56 enoximone 56 plasminogen activators 56 anticancer activity 56 dirucotide MBP# 56 antibiotic prophylaxis 56 antiplatelet agent 56 APTIVUS r 56 hematological parameters 56 pivotal bioequivalence 56 Elocalcitol 56 Targretin capsules 56 pramlintide metreleptin combination 56 urate lowering 56 CCR5 antagonist 56 paclitaxel Taxol 56 PEG Interferon lambda 56 pharmacologic stress 56 SILENOR TM 56 Zemplar Capsules 56 hA# 56 ExTRACT TIMI 56 metastatic neuroendocrine tumors 56 im peramivir 56 olanzapine LAI 56 warfarin dosage 56 acyclovir Lauriad R 56 castrate resistant prostate cancer 56 NEUMUNE 56 silico prediction 56 tramiprosate Alzhemed TM 56 L BLP# 56 tissue oxygenation 56 oral anticoagulation 56 TKM ApoB 56 IND submission 56 treprostinil 56 balloon brachytherapy 56 DORIBAX 56 vemurafenib 56 Phe restricted diet 56 Civacir 56 Egrifta 56 FOLPI 56 antimicrobial prophylaxis 56 PI3K/Akt pathway inhibitor 56 weekly subcutaneous injections 56 acadesine 56 recurrent glioblastoma multiforme 56 MET amplification 56 renoprotective 56 mapatumumab 56 convenient dosing regimen 56 CURE AF 56 Phase Ib 56 AeroLEF TM 56 ConclusionThis 56 dosing interval 56 Genz # 56 cardiac toxicity 56 Zybrestat 56 Tanespimycin 56 COPAXONE R 56 BAL# [002] 56 aminolevulinic acid ALA 56 periodically reassessed 56 faropenem 56 number NCT# ClinicalTrials.gov 56 AQ4N 56 SPC# [001] 56 Zenvia ™ 56 XL# SAR# 56 APTIMA HPV assay 56 pyridostigmine 56 physiologic mechanisms 56 trastuzumab DM1 56 Study GL# 56 ZK EPO 56 pharmacogenetic 56 Src inhibitors 56 AVONEX PEN 56 FASLODEX 56 EDEMA3 trial 56 intradermal injection 56 calcineurin inhibitors 56 USL# 56 CURRENT OASIS 7 56 NSABP B 56 DPP4 56 IGF 1R inhibitor 56 pioglitazone HCl 56 subcutaneous ORENCIA 56 Randomized controlled 56 Telatinib 56 radiation dosimetry 56 NeuVax 56 MEND CABG II 56 dopamine partial agonist 56 radiochemotherapy 56 anti emetic therapy 56 Vernakalant 56 investigational monoclonal antibody 56 NEUGENE 56 PEG PAL 56 OHR/AVR# 56 bevacizumab Avastin ® 56 electrophysiologic 56 oral gallium 56 endometrial hyperplasia 56 pralatrexate 56 XP #L 56 tumor hypoxia 56 AMEVIVE 56 mg/m2 dose 56 GPIIb IIIa 56 Interferon alpha 56 farletuzumab 56 serum biomarkers 56 TRV# [001] 56 administered subcutaneously 56 Quinamed 56 thrombin inhibiting aptamer 56 letrozole Femara 56 orally dosed 56 OvaRex ® MAb 56 antidiabetic medications 56 IoGen 56 genotoxicity studies 56 Prostate AdenoCarcinoma Treatment 56 APTIVUS ritonavir 56 antihypertensive therapy 56 immunosuppressive regimen 56 mertansine 56 reactogenicity 56 orally inhaled 56 metastatic RCC 56 R sorafenib tablets 56 delafloxacin 56 leukotriene receptor antagonists 56 folate supplementation 56 bisulfite sequencing 56 Fodosine 56 Trandolapril 56 tolevamer 56 Phase #b/#a clinical 56 Viramidine 56 IL# PE#QQR 56 subgroup analyzes 56 diagnostic biomarker 56 Abiraterone acetate 56 prostanoid 56 Altastaph 56 CYT# 56 masked placebo controlled 56 Thiovir 56 KRN# 56 Serdaxin 56 TRO# 56 clinically meaningful efficacy 56 chronic thromboembolic pulmonary 56 sunitinib 56 ESBA# 56 lanthanum carbonate 56 Phase IIb trials 56 β blockers 56 fenofibric acid 56 dose escalation phase 56 non pharmacological interventions 56 DVT prophylaxis 56 immunotherapeutic approaches 56 IFN beta 56 non selective NSAIDs 56 Fibrillex TM 56 VP# [004] 56 methylnaltrexone 56 relapsed SCLC 56 OVATURE 56 intravenous cyclophosphamide 56 NSABP C 56 uridine triacetate 56 interleukin IL -# 56 TEMODAL 56 PROSTVAC TM 56 HCV replicon 56 CUSTOM III 56 Urocidin 56 class mGluR5 inhibitor 56 flutamide 56 Insegia 56 lintuzumab SGN 56 efficacy endpoints 56 LEVADEX 56 VFEND 56 JAK inhibitors 56 Akt activation 56 palliative radiotherapy 56 intravenous immunoglobulin IVIg 56 Tamibarotene 56 Alzhemed TM 56 Altera Nebulizer System 56 adalimumab 56 secondary efficacy endpoints 56 infusional 56 Pimavanserin 56 pharmacogenetic tests 56 EGFR HER2 56 colon capsule endoscopy 55 refractory acute myeloid 55 catheter occlusion 55 primary hypercholesterolemia 55 MVax 55 allogeneic HSCT 55 aleglitazar 55 Cardiorespiratory fitness 55 bronchodilation 55 histamine dihydrochloride 55 parathyroid hormone PTH 55 RGB # 55 Intervention Effectiveness 55 icatibant 55 Raptiva ® 55 dasatinib Sprycel 55 MEND CABG 55 relapsed ovarian cancer 55 mycophenolate mofetil 55 taribavirin 55 cetrorelix 55 Oral corticosteroids 55 MoxDuo TM IR 55 radezolid 55 Insulin detemir 55 ATACAND 55 randomized multicenter Phase III 55 ImmunoVEX HSV2 55 Dapagliflozin 55 Spiegelmer ® 55 pharmacologic 55 oral talactoferrin 55 bexarotene

Back to home page